Semaglutide Online Review

Our assessment

Semaglutide Online puts both routes on one page — a compounded lane and an FDA-approved brand lane — and states, in a line of its own above the brand cards, that every brand medication needs a separate monthly subscription on top of the drug. That's the disclosure most sellers bury. It also publishes a long essay about the pricing tricks other telehealth brands use, one of which is the starting-at headline its own compounded semaglutide card uses. The compounded tirzepatide card doesn't make that mistake: it prints a flat figure and says outright that it covers every dose strength.

Both routes, priced side by side

Each drug page carries two blocks. The compounded block prices an injectable and an oral preparation, both marked as covering medication, provider review and shipping. The brand block prices the FDA-approved products by name — two injectable pens and an oral tablet on the semaglutide page, two pen formats on the tirzepatide page.

Very little of this comparison prints a brand cash figure at all, and less prints it beside a compounded one on the same screen. That's the reason to read this site.

The brand figures come with a caveat the seller supplies itself: the homepage attributes them to a federal price portal rather than to a rate it sets. So they can move without anything changing on this page.

The subscription is stated, not buried

Above the brand cards sits a single line saying every brand-name medication requires a monthly subscription in addition to the cost of the medication, and each brand card is separately labeled medication only, provider fee separate.

The compounded cards say the opposite in as many words: the figure is all-inclusive and covers the medication, the provider review and the shipping. The tirzepatide page adds that there are no hidden membership charges.

So the two regimes are distinguishable, which is the whole point. Don't set a brand headline beside a compounded one — they aren't the same claim, and the brand one is missing a charge.

It writes the warning and then does the thing

The site publishes a transparency report with a decoder of misleading pricing phrases. Its first entry is the starting-at headline, which it correctly describes as a base price for the lowest dose that rises as the dose climbs. Its commitments section promises all-inclusive pricing shown before intake and no dose-up fees.

The compounded semaglutide card then prints its figure as an as-low-as rate, offers one, three and five month options, and gives no price for any of the three. Which term produces the advertised figure is published nowhere.

The compounded tirzepatide card is the counter-example, and it shows the seller can do it: a flat figure, all doses, with a sentence beneath saying the price covers every dose strength.

What it will not tell you

No compounding pharmacy is named. The pages say the medication is prepared by FDA-registered facilities and refer to a partner pharmacy, and that's as specific as it gets.

No individual clinician is named either — not a medical director, not a prescriber, not on the drug pages and not in the transparency report.

There's no list of states served. The homepage names one state it doesn't serve, which is more than many sellers manage, but a single exclusion isn't a census and the rest is left to the intake screen.

Refund conduct is spelled out: if you aren't approved you aren't charged, and if you've already paid you're refunded. Read the thirty-day satisfaction guarantee carefully, though — it covers the evaluation, not the medication.